Bispecific antibody

TW202626739APending Publication Date: 2026-07-01ONO PHARMA CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: TW115109506
Authority / Receiving Office: TW · TW
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2020-02-13
Filing Date: 2020-04-01
Publication Date: 2026-07-01

Application Information

Patent Timeline

13 Feb 2020

Priority

01 Apr 2020

Application

TW115109506

01 Jul 2026

Publication

TW202626739A

IPC: C07K16/28; A61K39/395; A61P37/00; C07K16/46

Inventors: 柴山史朗; 手塚智也

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

An object of the present invention is to provide a new drug for prevention, suppression of symptom progression, recurrence suppression or treatment for autoimmune diseases. As a result of diligent studies, the inventors of the present invention have focused attention on PD-1 / CD19 bispecific antibody and the like as a substance capable of solving such problems, and confirmed that the bispecific antibody can be a new drug for prevention, suppression of symptom progression, suppression of recurrence or treatment for autoimmune diseases. In addition, it was confirmed that the bispecific antibody has a characteristic that allows interaction with PD-1 and its ligand, PD-L1.

Need to check novelty before this filing date? Find Prior Art